6 January 2012 GB0001646941/GBP/PLUS-exn EDEN RESEARCH PLC ("Eden" or the "Company") Teva Animal Health, Inc. exercises option that provides exclusive license rights with Eden * Exclusive license agreement for NAFTA region * Culmination of two years product development and trial work * USD 100,000 fee received with further milestones and royalties on product sales Eden Research plc, the agrochemical and encapsulation development company, is pleased to announce that, following extensive development and trials, Teva Animal Health, Inc. ("TAH") has formally decided to exercise its option and thereby enter into a licensing agreement with Eden. The licensing agreement gives TAH the exclusive rights to develop, manufacture and market products in the future for the treatment of common bacterial, fungal, and/or parasitic pathogens in the veterinary health space in the North American Free Trade Agreement ("NAFTA") region. In addition to the USD 100,000 licence fee received, the agreement provides for TAH to pay further milestone payments totalling USD 800,000, plus royalty payments once sales of the products begin. Clive Newitt, Managing Director of Eden, said, "We have been working closely with TAH since January 2010 to help develop products which meet their needs for treating various issues in veterinary health. I'm delighted that the result of this work is a formal, exclusive licensing agreement with a subsidiary of one of the largest pharmaceutical companies in the world. The fact that we have reached this commercial agreement with such a major, global company as Teva Animal Health Inc. underpins the efficacy and commercial potential of our products." The Directors of Eden are responsible for the contents of this announcement. Enquiries: Eden Research plc 01993 862761 Clive Newitt, Managing Director St Helens Capital Partners LLP 020 7368 6959 Mark Anwyl Threadneedle Communications 020 7653 9850 Josh Royston, Beth Harris Notes: Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries. Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals. The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness. The UMMS license also significantly expands the potential use of the Eden technology in non- agricultural applications such as health and beauty, cosmetics and animal health. For more information about Eden, please visit [ www.edenresearch.com ]

Contributing Sources

---

Market Wire